Concepedia

David R. D’Adamo

DR

42

Publications

6.2K

Citations

31

H-Index

1997

Active since

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Dana-Farber Cancer Institute

Eisai (United States)

Texas Oncology

Massachusetts General Hospital

David R. D’Adamo is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, pathology, and oncology.

Top concepts

Publications per year

1997–2023

42

Publications

42

Crizotinib in<i>ALK</i>-Rearranged Inflammatory Myofibroblastic Tumor

James E. Butrynski, David R. D’Adamo, Jason L. Hornick et al. · New England Journal of Medicine · 2010 · 851 citations

, , +9

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Patrick Schöffski, Sant P. Chawla, Robert G. Maki et al. · The Lancet · 2016 · 753 citations · Full text

, , +6

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

Robert G. Maki, David R. D’Adamo, Mary Louise Keohan et al. · Journal of Clinical Oncology · 2009 · 569 citations · Full text

, , +13

Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Manish A. Shah, Ramesh K. Ramanathan, David H. Ilson et al. · Journal of Clinical Oncology · 2006 · 409 citations

Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas

Suzanne George, Priscilla Merriam, Robert G. Maki et al. · Journal of Clinical Oncology · 2009 · 315 citations · Full text

, , +12

Rows per page

1–5 of 42